INMB shareholder-approved one-time option repricing sets strike at $1.50
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Inmune Bio, Inc. (INMB) reported a change in the stock options held by its interim CFO, Cory Randall Ellspermann. On November 18, 2025, shareholders approved a one-time repricing of certain outstanding options granted under the company’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the exercise price of each affected option to $1.50 per share, which was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date.
The Form 4 shows cancellations of existing stock options with higher exercise prices and the grant of replacement options at the new $1.50 exercise price for the same numbers of underlying shares and original expiration dates. All other terms of these options, including vesting schedules and overall terms, remain unchanged and continue to depend on the executive’s ongoing service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Ellspermann Cory Randall
Role
Interim CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 75,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 75,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 40,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 40,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 70,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 70,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 0 shares (Direct)
Footnotes (1)
- Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What did Inmune Bio (INMB) disclose in this Form 4 filing?
Inmune Bio disclosed that its interim CFO, Cory Randall Ellspermann, had certain existing stock options repriced to a new exercise price, with the changes reported as option dispositions and new option grants on the same underlying share amounts.
What is the new exercise price of the repriced INMB stock options?
The affected stock options now have an exercise price of $1.50 per share, which represents the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on the repricing date.
When were the Inmune Bio (INMB) option repricing changes approved?
The option repricing became effective on November 18, 2025, when Inmune Bio’s stockholders approved a one-time repricing of certain outstanding stock options held under its equity incentive plans.
Which equity plans are involved in the INMB option repricing?
The repriced options were granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan, and Second Amended and Restated 2021 Stock Incentive Plan.
Did the vesting terms of the repriced INMB options change?
No. The company states that, apart from the new $1.50 exercise price, all other terms and conditions of the repriced options, including vesting schedules and overall terms, remain in full force and effect.
Whose options were affected by this INMB Form 4 transaction?
The Form 4 relates to stock options held by Cory Randall Ellspermann, who serves as Inmune Bio’s interim Chief Financial Officer and is listed as the sole reporting person on the filing.